

## Special Issue

# Uremic Toxins and Hemodialysis: Mechanisms, Challenges, and Therapeutic Advances

### Message from the Guest Editors

Hemodialysis (HD) is the world's most widely used renal replacement therapy for the management of end-stage kidney disease. Despite technological advances, plasma depuration performances remain limited and the accumulation of unremoved uremic toxins is still a major unsolved problem. Moreover, because of the comorbidities frequently associated with advanced age (diabetes, hypertension, cardiovascular disease, overweight, dyslipidemia, smoking, etc.), access to transplantation will not be possible for the vast majority of patients worldwide. Research is therefore still needed to better understand the key pathophysiological mechanisms behind the deleterious impact of uremic toxins on oxidative stress, endothelial dysfunction, and alterations to the microbiota, among other issues. Indeed, the therapeutic strategies depend on such research—whether they be medicinal or dietary, or combined with more sophisticated purification techniques. More than ever, an interdisciplinary approach to basic and clinical research on HD patients is crucial to improve the currently unfavorable overall prognosis linked to the numerous multi-systemic consequences.

### Guest Editors

Prof. Dr. Joëlle Nortier


1. Laboratory of Experimental Nephrology, Faculty of Medicine, Université Libre de Bruxelles, Erasme Campus, 808 Route de Lennik, 1070 Brussels, Belgium
2. Nephrology & Dialysis Department, University Hospital Brugmann, Université Libre de Bruxelles, 4 Place Van Gehuchten, 1020 Brussels, Belgium

Prof. Dr. Marie-Hélène Antoine

Laboratory of Experimental Nephrology, Faculty of Medicine, Université Libre de Bruxelles, Erasme Campus, 808 Route de Lennik, 1070 Brussels, Belgium

### Deadline for manuscript submissions

31 October 2026



## Toxins

an Open Access Journal  
by MDPI

Impact Factor 4.0  
CiteScore 8.3  
Indexed in PubMed



[mdpi.com/si/245531](https://mdpi.com/si/245531)

*Toxins*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[toxins@mdpi.com](mailto:toxins@mdpi.com)

[mdpi.com/journal/  
toxins](https://mdpi.com/journal/toxins)





# Toxins

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.0  
CiteScore 8.3  
Indexed in PubMed



[mdpi.com/journal/  
toxins](https://mdpi.com/journal/toxins)



## About the Journal

### Message from the Editor-in-Chief

Toxinology is an incredibly diverse area of study, ranging from field surveys of environmental toxins to the study of toxin action at the molecular level. The editorial board and staff of *Toxins* are dedicated to providing a timely, peer-reviewed outlet for exciting, innovative primary research articles and concise, informative reviews from investigators in the myriad of disciplines contributing to our knowledge on toxins. We are committed to meeting the needs of the toxin research community by offering useful and timely reviews of all manuscripts submitted. Please consider *Toxins* when submitting your work for publication.

---

### Editor-in-Chief

Prof. Dr. Jay Fox

Department of Microbiology, University of Virginia, Charlottesville, VA,  
USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Toxicology) / CiteScore - Q1 (Toxicology)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).